A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients.
- Registry ID
- EUCTR2008-000465-37
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE3
- Sponsor
- Laboratoires Merck Sharp & Dohme - Chibret
- Start date
- 2008-05-30
- Last update
- 2026-08-16
Conditions
- Dyslipidemia Dislipidemia
- Dyslipidemia
Summary
E.2.1 Main objective: To evaluate the efficacy of ER niacin/laropiprant 2g relative to placebo on plasma low-density lipoprotein cholesterol (LDL-C) at Week 12 of treatment.
Locations
- , , France
- , , Austria
- , , Netherlands
- , , Spain
Related clinical trials
- A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
- Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
- Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
- A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
- Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
View on source registry